Articles in IPOs

Renaissance Capital

A blank check for biotechs: CB Pharma Acquisition files and sets terms for $40 million IPO

CB Pharma Acquisition, a biotech focused blank check company backed by Coronado Biosciences, announced terms for its IPO on Thursday. The Burlington, MA based company plans to raise $40 million by... Read >>

Renaissance Capital

EndoStim postpones $35 million IPO

EndoStim, which sells a neurostimulation device used to treat gastroesophageal reflux disease, postponed its IPO on Thursday citing poor market conditions. The St. Louis, MO based company was... Read >>

Renaissance Capital

Micro-cap research firm Sidoti & Company files for a $35 million IPO

Sidoti & Company, a leading provider of equity research on small and micro cap public companies, filed on Thursday with the SEC to raise up to $35 million in an initial public offering. Sidoti... Read >>

Renaissance Capital

Sky Solar Holdings sets terms for $138 million IPO

Sky Solar Holdings, an independent power producer with solar assets mainly in Greece and Japan, announced terms for its IPO on Wednesday. The Hong Kong based company plans to raise $138 million by... Read >>

Renaissance Capital

Female sexual dysfunction biotech S1 Biopharma sets terms for $36 million IPO

S1 Biopharma, a biotech developing a combined therapy of existing drugs for female sexual dysfunction, announced terms for its IPO on Wednesday. The New York, NY based company plans to raise $36... Read >>

Renaissance Capital

NASH/HIV biotech Tobira Therapeutics revives IPO plans; updates financials and underwriters

Tobira Therapeutics, a biotech developing an immunotherapy treatment for liver disease ( NASH ) and HIV, revived plans for its upcoming IPO in an amendment filed on Tuesday with blank terms and... Read >>

Renaissance Capital

DBV Technologies prices US IPO at $21.64, below expectations

DBV Technologies, a French biotech developing immunotherapy patches that treat food allergies, raised $93 million by offering 4.3 million shares at $21.64, below its $23 proposed offer price. DBV... Read >>

Renaissance Capital

Put your back into it: The Joint sets terms for $30 million IPO

The Joint, which franchises 215 cash based chiropractic clinics in the US, announced terms for its IPO on Wednesday. The Scottsdale, AZ based company plans to raise $30 million by offering 3.0... Read >>

Renaissance Capital

Fifth Street Asset Management withdraws IPO, citing market volatility

Fifth Street Asset Management, a credit focused alternative asset manager with $5.6 billion in AUM, postponed its IPO on Wednesday citing market volatility. The Greenwich, CT based company was... Read >>

Renaissance Capital

Proteon Therapeutics prices IPO at $10, below the range

Proteon Therapeutics, which is developing a treatment to reduce the failure rates of a dialysis related procedure, raised $61 million by offering 6.1 million shares at $10, below the range of $12... Read >>

Displaying 1-10 of 2829
<< first < previous 1 2 3 4 5 50 100 150 200 250 last >>